Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Adva
To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line
| Condition(s) | Esophageal Cancer by AJCC V8 Stage |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line |
| Who can participate | Inclusion Criteria: * 1\. Age 18-75, male or female; * 2\. Esophageal squamous cell carcinoma that is histologically or cytologically confirmed as unresectable locally advanced/recurrent (unable to receive radical treatment such as radical chemoradiotherapy or radical radiotherapy) or distant metastasis; * 3\. No previous systematic antitumor therapy. For patients who received neoadjuvant/adjuvant and radical concurrent chemoradiotherapy, the time from the last chemotherapy to recurrence or progression more than 6 months can be screened; * 4\. According to the efficacy evaluation criteria for solid tumors (RECIST 1.1), there should be at least one measurable lesion (esophageal and other cavity structures cannot be used as measurable lesions), and the measurable lesions should not have rece |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | The First Affiliated Hospital of Zhengzhou University |
| Locations | Zhengzhou, Henan, China |
| Start date | 2023-03-02 |
| NCT ID | NCT05738434 |
| Official listing | https://clinicaltrials.gov/study/NCT05738434 |